AngioDynamics Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:5em;'>A</div>
ANGO -- USA Stock  

USD 11.07  0.16  1.47%

AngioDynamics is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 29th of September 2020. The stock is in a buyout trend. While some baby boomers are getting worried about their positions in healthcare space, it is entirely reasonable to outline AngioDynamics as a possible position for your existing portfolio. I will address why institutional investors ignored this entity since the beginning of the latest economic outlook.
Published over three weeks ago
View all stories for AngioDynamics | View All Stories
Our latest take on AngioDynamics (NASDAQ:ANGO) analyst consensus
AngioDynamics is UNDERVALUED at 11.10 per share with modest projections ahead. Our trade advice tool can cross-verify current analyst consensus on AngioDynamics and to analyze the company potential to grow in the current economic cycle.
What is the right price you would pay to acquire a share of AngioDynamics? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with AngioDynamics this year

Annual and quarterly reports issued by AngioDynamics are formal financial statements that are published yearly and quarterly and sent to AngioDynamics stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as AngioDynamics often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How AngioDynamics utilizes its cash?

To perform a cash flow analysis of AngioDynamics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash AngioDynamics is receiving and how much cash it distributes out in a given period. The AngioDynamics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. AngioDynamics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (14.94 Million)

Acquisition by Tarnoff Michael E of 15323 shares of AngioDynamics subject to Rule 16b-3

Legal trades by AngioDynamics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
AngioDynamics insider trading alert for grant of common stock by Tarnoff Michael E, the corporate stakeholder, on 16th of September 2020. This event was filed by Angiodynamics Inc with SEC on 2020-09-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is AngioDynamics a risky opportunity?

Let's check the volatility. AngioDynamics is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind AngioDynamics (NASDAQ:ANGO) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. picking up a share of an AngioDynamics stock makes you a part-owner of that company.

AngioDynamics Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering AngioDynamics. The AngioDynamics consensus assessment is calculated by taking the average estimates from all of the analysts covering AngioDynamics

Strong Buy00.0
Strong Sell00.0

Will AngioDynamics latest rise continue?

The market risk adjusted performance is down to 0.24 as of today. AngioDynamics shows above-average downside volatility for the selected time horizon. We advise investors to inspect AngioDynamics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of AngioDynamics future alpha.

Our Final Take On AngioDynamics

When is the right time to buy or sell AngioDynamics? Buying stocks such as AngioDynamics isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor drop any shares of AngioDynamics at this time. The AngioDynamics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to AngioDynamics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of AngioDynamics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to